Fruquintinib Plus Serplulimab as First-Line Therapy in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (nccRCC): Updated Efficacy and Safety from a Multicenter, Single-Arm Trial
讲者:黄吉炜
单位:上海交通大学医学院附属仁济医院
Prognostic risk factors of pneumonia associated with COVID-19 in patients with lymphoma
讲者:刘丹
单位:山东省肿瘤医院
DNA甲基化在预测新辅助化放疗联合抗PD-1抗体治疗局部晚期食管鳞状细胞癌疗效中的预后价值
讲者:李梓萌
单位:中山大学肿瘤防治中心
Preliminary results of Phase II Study on HB0025 (a PD-L1/VEGF Trap Antibody Fusion) with Chemotherapy as First-Line Treatment for advanced Non-Small Cell Lung Cancer (NSCLC)
讲者:熊安稳
单位:上海市东方医院
维迪西妥单抗联合呋喹替尼用于既往至少接受过2种标准治疗失败的HER2表达或突变的晚期结直肠癌的单臂、前瞻性、探索性临床研究
讲者:高毓
单位:武汉大学中南医院
First-line PD-1 Blockades Combined with TKIs for Metastatic Non-clear Cell Renal Cell Carcinoma: A Real-world Multicenter Retrospective Study
讲者:钟曦
单位:中山大学肿瘤中心
早期乳腺癌术后的超短程全乳放疗序贯瘤床加量(SHIFT):一项多中心II期试验的安全性结果
讲者:徐菲菲
单位:上海交通大学医学院附属瑞金医院
新辅助化疗-免疫治疗后肺鳞癌患者肿瘤引流与非引流淋巴结免疫异质性的单细胞组学分析
讲者:张朋朋
单位:天津医科大学肿瘤医院
A Phase II Study of NALIRIFOX (Liposomal Irinotecan, 5-Fluorouracil, Leucovorin and Oxaliplatin) in Patients with Locally Advanced Pancreatic Cancer (LAPC)
讲者:涂敏
单位:南京医科大学附属第一医院
Encorafenib and cetuximab versus irinotecan/cetuximab or FOLFIRI/cetuximab in Chinese patients with BRAFV600E mutant metastatic colorectal cancer: efficacy and safety results from the final analysis - NAUTICAL CRC study
讲者:许婷
单位:北京大学肿瘤医院